Donald Trump: Catching COVID-19 a ‘Blessing in Disguise’ Because of Regeneron Drug

A Message from the President

President Donald Trump on Wednesday described his illness with COVID-19 as a “blessing in disguise” because of his treatment with the experimental drug Regeneron.

“I think this was a blessing from God that I caught it. This is a blessing in disguise,” Trump said in a video posted to social media.

The president said that when he went to Walter Reed Hospital, he asked his doctors about taking Regeneron’s drug to treat COVID-19. The company provided the drug to Trump in response to a compassionate use request from his doctors. The drug is an antibody cocktail called REGN-COV2. The drug has not been approved by the Food and Drug Administration although it is in a phase three trial that began in July.

“I went in, I wasn’t feeling so hot, and within a very short period of time then they gave me Regeneron … I think this was the key … It was like unbelievable, I felt good immediately,” Trump said.

“To me, it wasn’t therapeutic, it just made me better,” he continued. “I call that a cure.”

The president also promoted a similar antibody drug under development by Eli Lilly and Company seeking approval from the Federal Drug Administration.

“That’s what I want for everybody, I want everybody to be given the same treatment as your president, because I feel great,” he said.

Trump said he wanted to make the drug available for the rest of Americans and also make it free.

“If you’re in the hospital, and you’re feeling really bad, I think we’re going to work it so that you’re going get them, and you’re going to get them free,” he said. “Especially if you’re a senior, we’re going to get you in there quick.”

Trump admitted that the COVID-19 vaccine would not be developed before the election, despite his best efforts to get it done.

“I think we should have it before the election, but politics gets involved and that’s ok. They want to play their games, it’s going to be right after the election,” he said.


Please let us know if you're having issues with commenting.